.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKesson
Covington
Baxter
Deloitte
Express Scripts
Cantor Fitzgerald
Chubb
US Army
Fish and Richardson
Cerilliant

Generated: July 26, 2017

DrugPatentWatch Database Preview

VIEKIRA XR Drug Profile

« Back to Dashboard

Which patents cover Viekira Xr, and when can generic versions of Viekira Xr launch?

Viekira Xr is a drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this drug.

This drug has four hundred and sixty-two patent family members in fifty-one countries.

The generic ingredient in VIEKIRA XR is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.

Summary for Tradename: VIEKIRA XR

Patents:18
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list4
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIEKIRA XR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VIEKIRA XR
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIEKIRA XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,255,092Polymorph of a pharmaceutical► Subscribe
8,969,357Methods for treating HCV► Subscribe
9,452,194Methods for treating HCV► Subscribe
8,691,878Solid pharmaceutical dosage form► Subscribe
8,937,150Anti-viral compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIEKIRA XR

Country Document Number Estimated Expiration
China101163479► Subscribe
Japan5834085► Subscribe
Germany202012012954► Subscribe
Germany112012003457► Subscribe
Japan2013528225► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIEKIRA XR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0730Netherlands► SubscribePRODUCT NAME: PARITAPREVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
2015013,C2203431Lithuania► SubscribePRODUCT NAME: DASABUVIRAS; REGISTRATION NO/DATE: EU/1/14/983 20150115
2368890/01Switzerland► SubscribePRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
/2015Austria► SubscribePRODUCT NAME: PARITAPREVIR, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ANNEHMBARER ESTER DAVON; REGISTRATION NO/DATE: (MITTEILUNG VOM 19.1.2015) EU/1/14/982 20150115
2015012Lithuania► SubscribePRODUCT NAME: OMBITASVIRUM; REGISTRATION NO/DATE: EU/1/14/982 20150115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Accenture
Cantor Fitzgerald
Express Scripts
QuintilesIMS
Covington
Julphar
McKinsey
UBS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot